Andrew Huberman has been characteristically transparent about his personal experimentation with peptide therapeutics, though his experience has been limited and cautious. During his comprehensive discussion of peptides on the Huberman Lab podcast, he revealed specific details about his own use—or more accurately, his limited use and subsequent discontinuation of certain compounds.
The only peptide Huberman explicitly confirmed taking is sermorelin, a growth hormone-releasing peptide. “I’ll just be completely forthcoming,” he stated, “I’ve taken sermorelin on and off for the last couple of years. I typically will take it anywhere from one to two nights per week.” His dosing regimen falls within the standard therapeutic range, though he emphasized taking it infrequently rather than daily.
However, Huberman’s sermorelin experiment didn’t have the outcome he hoped for. He explained that he “stopped taking it almost completely” after noticing problematic effects on his sleep architecture.
“The reason I stopped taking it is that I noticed that it made the sleep in the early part of my night very very deep, very robust, but then I would wake up wide awake,” he reported. More concerning was the impact on his REM sleep: “At least according to my eight sleep sleep tracker or my whoop sleep tracker, I wasn’t getting nearly as much rapid eye movement sleep as I normally would.”
This trade-off between deep sleep and REM sleep proved unacceptable. As Huberman explained, sermorelin “seemed to sort of replace rapid eye movement sleep with more deep sleep, and rapid eye movement sleep is critical for all sorts of things that deep sleep can’t achieve and vice versa, so you really want both.”
His conclusion was clear: “This is one reason why I’ve basically stopped taking sermorelin. I’ll occasionally take it every once in a while, but in general I just stop taking it because whatever the positive effects might have been if I had taken it more consistently, the effects in depleting rapid eye movement sleep were just something I didn’t want and don’t want.”
Huberman was equally explicit about what he doesn’t take. He made no mention of using BPC-157, despite discussing it extensively. He didn’t claim personal experience with thymosin beta-4, hexarelin, ipamorelin, or any of the melanocortin peptides. His discussion of kisspeptin, epithalon, and other longevity-related peptides remained purely educational, with no indication of personal use.
His overall stance reflects scientific caution rather than enthusiasm. While acknowledging that many people report benefits from various peptides, Huberman emphasized repeatedly that he’s “certainly not suggesting anyone run out and take” these compounds. His personal experimentation appears to have reinforced his conservative approach, leading him to abandon even the relatively well-studied and FDA-approved sermorelin due to sleep disruption—a side effect that, while documented in the literature, proved intolerable in his own experience.